Natera, Inc. $NTRA Holdings Lifted by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Natera, Inc. (NASDAQ:NTRA) by 283.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,571 shares of the medical research company’s stock after purchasing an additional 13,734 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Natera were worth $3,142,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of NTRA. Bank of Jackson Hole Trust bought a new position in Natera in the 1st quarter worth about $29,000. TCTC Holdings LLC grew its position in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank bought a new position in Natera in the 2nd quarter valued at about $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera in the second quarter valued at approximately $36,000. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, Director Rowan E. Chapman sold 2,750 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,491 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total transaction of $403,666.55. Following the completion of the transaction, the chief financial officer directly owned 69,189 shares of the company’s stock, valued at $11,212,077.45. This represents a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 224,889 shares of company stock worth $43,232,062. Company insiders own 5.63% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $196.45 on Wednesday. Natera, Inc. has a one year low of $122.08 and a one year high of $203.23. The company has a 50-day moving average of $175.77 and a two-hundred day moving average of $162.77. The stock has a market cap of $26.96 billion, a price-to-earnings ratio of -102.85 and a beta of 1.75.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the business posted ($0.30) EPS. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NTRA. Stephens reiterated an “overweight” rating and issued a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Cowen restated a “buy” rating on shares of Natera in a report on Friday, August 8th. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 target price for the company in a report on Monday, July 28th. Morgan Stanley restated an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $194.89.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.